Brodalumab IL-17RA blockade demonstrates rapid, durable efficacy in plaque psoriasis and psoriatic arthritis

Psoriasis, including plaque psoriasis and psoriatic arthritis, is a systemic inflammatory disease often linked to cardiometabolic comorbidities like obesity and cardiovascular disease. The interleukin-17 (IL-17) signaling axis is central to its pathogenesis, driving inflammation. Current treatments may not always achieve complete skin clearance or adequately address joint symptoms, leaving a gap for therapies with distinct mechanisms. Targeting the IL-17 pathway offers a promising approach to interrupt this inflammatory cascade.

This review synthesized evidence from pivotal randomized controlled trials and extensive real-world studies to evaluate brodalumab's efficacy, safety, and clinical positioning. It contextualized IL-17RA blockade across the spectrum of psoriatic disease, including plaque psoriasis and psoriatic arthritis. The authors aimed to provide a comprehensive overview of brodalumab's performance in diverse patient subgroups and its implications for clinical practice.

Brodalumab, a fully human monoclonal antibody targeting IL-17RA, consistently demonstrated a rapid onset of action across both randomized trials and real-world studies. The evidence showed high rates of complete skin clearance, indicating potent efficacy in plaque psoriasis. Furthermore, brodalumab maintained durable efficacy and consistent effectiveness across diverse patient subgroups, suggesting broad applicability. For patients with concomitant psoriatic arthritis, the review highlighted meaningful improvements in joint outcomes. This distinct mechanism of IL-17 inhibition via receptor blockade offers a unique therapeutic profile. Safety data from both randomized and real-world settings supported its tolerability. > Brodalumab provides a mechanistically distinct approach to inhibiting IL-17–mediated inflammation, showing rapid onset and high rates of complete skin clearance.